Human papillomavirus type 6 E6 and E7 oncoproteins (HPV6 E6/E7)

Human papillomavirus type 6 (HPV6) E6 and E7 are early viral oncoproteins that play a central role in the pathogenesis of low-risk HPV-related diseases, most notably genital warts and recurrent respiratory papillomatosis (RRP) (National Cancer Institute, 2023). These proteins function by subverting host cell cycle control; E7 binds to the retinoblastoma protein (pRb) to trigger S-phase entry, while E6 interacts with various cellular factors to promote cell survival and viral replication (PubMed, PMID: 28926984). Although HPV6 is considered low-risk because it rarely leads to malignancy, the E6 and E7 proteins are constitutively expressed in infected cells, making them specific and ideal targets for therapeutic intervention (UniProt, 2024). Current drug development focuses on therapeutic vaccines like PRGN-2012 and INO-3106, which are designed to elicit a robust T-cell-mediated immune response against these viral antigens (Precigen, 2024; Inovio Pharmaceuticals, 2023). By training the immune system to recognize E6 and E7, these therapies aim to selectively eliminate infected cells, thereby reducing viral load and inducing the regression of clinical lesions. This approach is particularly valuable for chronic or recurrent conditions where surgical intervention is insufficient to prevent relapse.

Other names

HPV6 E6/E7-expressing cellsHPV-6 E6 and E7 proteinsHuman papillomavirus 6 early proteinsHPV6-infected cells

Therapeutic vaccines and immunotherapies target these proteins by delivering genetic sequences (DNA or viral vectors) that encode HPV6 E6 and E7 antigens to host cells. These antigens are then presented on MHC class I molecules, which activates a cytotoxic T-lymphocyte (CTL) response specifically directed at recognizing and lysing HPV6-infected cells (ClinicalTrials.gov, NCT04724980). Other treatments, such as imiquimod, act as immune response modifiers by stimulating toll-like receptor 7 (TLR7) to enhance the local innate and adaptive immune environment against the infected cells (PubChem, 2024).